The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety.

Charles E LeonardColleen M BrensingerGhadeer K DawwasRajat DeoWarren B BilkerSamantha E SopranoNeil DhopeshwarkarJames H FloryZachary T BloomgardenJoshua J GagneChristina L AquilanteStephen E KimmelSean Hennessy

Published in: Cardiovascular diabetology (2020)

Rosiglitazone and pioglitazone appear to be associated with similar risks of SCA/VA.

Keyphrases

cardiac arrest
catheter ablation
cardiopulmonary resuscitation
heart failure
left ventricular
human health
atrial fibrillation
risk assessment